Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Amolyt Pharma logo — Advancing peptides for the treatment of rare endocrine and r...

Amolyt Pharma

Advancing peptides for the treatment of rare endocrine and related diseases

Founded 2015 France France 37 employees Series C Total: $291.20M Biotechnology, Health Care +2

General Information

Company Name Amolyt Pharma
Founded Year 2015
Location France France
Founders / Decision Makers
Team member
Employees 37
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Amolyt Pharma. To contact Amolyt Pharma, visit amolytpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Amolyt Pharma compare?

A PDF of Amolyt Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Amolyt Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Amolyt Pharma

Amolyt Pharma is a biotechnology company founded in 2015, headquartered in France, and dedicated to developing innovative treatments for rare endocrine and related diseases. The company's slogan "Advancing peptides for the treatment of rare endocrine and related diseases" underscores its focus on using peptides to address unmet medical needs in the field. Amolyt Pharma's portfolio features eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist intended for treating hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist designed for potential use in treating acromegaly. The company has garnered attention and investment from a strong syndicate of international investors, including Kurma Partners, Pontifax, Sofinnova Partners, OrbiMed, Intermediate Capital Group, Sectoral Asset Management, Turenne Capital, Mass General Brigham Ventures, Tekla Capital Management, and Novo Ventures, who collectively contributed a significant €130.00M Series C investment on 06 January 2023. Amolyt Pharma is well-positioned to expand its portfolio and advance its groundbreaking treatments by leveraging its global network in the field of endocrinology. With its compelling mission and support from reputable investors, the company is poised to make significant strides in transforming the landscape of rare disease therapeutics.

Business keywords: Therapeutic Peptides, Rare Disease Treatment, Endocrinology, Metabolic Disorder Treatment, Hypoparathyroidism, Acromegaly, Peptide Drug Development, Endocrine Disease, Biopharmaceuticals, Clinical Research, Global Network, Investor Syndicate

Services & Products

Biopharmaceutical research and development
clinical trials
precision medicine
healthcare delivery

Target Customers

Patients healthcare providers research institutions pharmaceutical industry

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Series C €130.00M 10
Kurma Partners Pontifax Sofinnova Partners
Kurma Partners, Pontifax +8
06 Jan 2023
Series B $80.00M 10
Kurma Partners Pontifax OrbiMed
Kurma Partners, Pontifax +8
16 Sep 2021
Venture Round Undisclosed 1
Euazeo
Euazeo
08 Aug 2020
Series A €67.00M 10
Bpifrance Kurma Partners Pontifax
Bpifrance, Kurma Partners +8
31 Jul 2019
Venture Round €1.80M 5
Rhone-Alpes Creation Sofimac Investment Managers
Rhone-Alpes Creation, Sofimac Investment Managers +3
17 Mar 2015
Series A €5.00M 1
Bpifrance
Bpifrance
10 Sep 2014
Venture Round €3.30M 2
Sham, Octalfa
04 Jun 2012
Venture Round €3.00M 2
Sham, Octalfa
01 Sep 2009
Venture Round €1.10M 1
Octalfa
06 May 2008

Latest News

View All
Kurma Partners raises €140 million first close of new €250 million Biofund IV — Eu-startups
Kurma Partners raises €140 million first close of new €250 million Biofund IV
Eu-startups Oct 03, 2024
22 techbio soonicorns ready to cross the $1bn threshold — Sifted
22 techbio soonicorns ready to cross the $1bn threshold
Sifted Feb 22, 2024
These 12 startups could be France’s next unicorns — Sifted
These 12 startups could be France’s next unicorns
Sifted Feb 15, 2024

Amolyt Pharma Alternatives & Competitors

View All Alternatives
Amolyt Pharma vs
Gan & Lee Pharmaceuticals
Gan & Lee Pharmaceuticals China

Science & Excellence

Private Equity
379 employees
Biopharma, Biotechnology
Compare Amolyt Pharma vs Gan & Lee Pharmaceuticals
Amolyt Pharma vs
Medesis Pharma
Medesis Pharma France

Une technologie pour délivrer des médicaments dans toutes les cellules à partir d'une administration...

20 employees
Health and Wellness, Pharmaceutical
Compare Amolyt Pharma vs Medesis Pharma
Amolyt Pharma vs
NeuroScientific Biopharmaceuticals Ltd
NeuroScientific Biopharmaceuticals Ltd Australia

Novel drug therapies for neurodegenerative conditions

7 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Amolyt Pharma

Advancing peptides for the treatment of rare endocrine and related diseases
Amolyt Pharma was founded in 2015.
Amolyt Pharma is headquartered in France.
Amolyt Pharma operates in Biotechnology, Health Care, Health and Wellness and Pharmaceutical. Its work centres on Therapeutic Peptides, Rare Disease Treatment, Endocrinology and Metabolic Disorder Treatment. Its customers include Patients, healthcare providers and research institutions.
Amolyt Pharma has approximately 37 employees.
Amolyt Pharma has completed 9 funding rounds, raising a total of $291.20M. The latest funding stage is Series C.
Amolyt Pharma offers: Biopharmaceutical research and development, clinical trials, precision medicine, healthcare delivery.
Top alternatives and competitors to Amolyt Pharma include Gan & Lee Pharmaceuticals, Medesis Pharma, NeuroScientific Biopharmaceuticals Ltd, Viking Therapeutics, Inc., Soleno Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Amolyt Pharma and Gan & Lee Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Amolyt Pharma, https://bouncewatch.com/company/amolyt-pharma, updated 11 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout